Cart
sales@molnova.com
Larotinib
CAS No. 1438072-11-7
Larotinib( —— )
Catalog No. M36515 CAS No. 1438072-11-7
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 112 | Get Quote |
|
| 5MG | 170 | Get Quote |
|
| 10MG | 258 | Get Quote |
|
| 25MG | 426 | Get Quote |
|
| 50MG | 609 | Get Quote |
|
| 100MG | 835 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameLarotinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionLarotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR.
-
DescriptionLarotinib is a potent broad-spectrum and orally active tyrosine kinase inhibitor (TKI) with EGFR as the main target with an IC50 of 0.6 nM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetBTK
-
RecptorBTK | Tyrosine Kinases | IRAK | EGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1438072-11-7
-
Formula Weight488.94
-
Molecular FormulaC24H26ClFN4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESN(C=1C2=C(C=C(OC)C(OCCCN3C[C@@]4([C@](C3)(OCCO4)[H])[H])=C2)N=CN1)C5=CC(Cl)=C(F)C=C5
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Liu J, et al. Phase I Trial to Evaluate the Tolerance, Pharmacokinetics and Efficacy of the Broad-Spectrum ErbB Family Inhibitor Larotinib Mesylate in Patients With Advanced Solid Tumors. Front Pharmacol. 2021 Feb 18;12:636324.?
molnova catalog
related products
-
AVL-292
AVL-292 (Spebrutinib, CC-292) is a highly selective, covalent Btk inhibitor with IC50 of <1 nM; also less potently inhibits Yes, c-Src, Brk, Lyn, and Fyn with IC50s of 723 nM, 1.729 uM, 2.43 uM, 4.4 uM, and 7.15 uM, rspectively.
-
LFM-A13
A highly specific inhibitor of BTK with Ki of 1.4 uM, IC50 of 17.2 uM.
-
BGB-8035
BGB-8035 is an orally available, selective and potent BTK inhibitor with antitumor activity that inhibits BTK, TEC and EGFR.BGB-8035 is used in the study of tumors and autoimmune diseases.
